Log in

Relevant bibliographies by topics / NeuroAiD / Journal articles

To see the other types of publications on this topic, follow the link: NeuroAiD.

Journal articles on the topic 'NeuroAiD'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'NeuroAiD.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kumar, Ramesh, Azizi Abu Bakar, Jegan Thanabalan, et al. "Safety and Use of MLC601/MLC901 (NeuroAiDTM) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry." Brain Sciences 10, no. 8 (2020): 499. http://dx.doi.org/10.3390/brainsci10080499.

Full text

Abstract:

Background: MLC601/MLC901 (NeuroAiD™) is a combination of natural products shown to be safe and to aid neurological recovery after brain injuries, especially ischemic stroke. Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH). The NeuroAiD Safe Treatment (NeST) Registry explores NeuroAiD use in the real-world setting. This cohort study aimed to assess its use and safety in ICH. Methods: The online NeST Registry of subjects with ICH given NeuroAiD prospectively collected clinical data at baseline and monthly visits (V) 1 to 3. Outcome measures included compliance,

APA, Harvard, Vancouver, ISO, and other styles

2

SALEH, ARMAN YURISALDI, Riezky Valentina, Tirta Darmawan Susanto, and Dwi Arwandi Yogi Saputra. "Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study." F1000Research 13 (July 16, 2024): 799. http://dx.doi.org/10.12688/f1000research.152581.1.

Full text

Abstract:

Introduction NeuroAiD, also known as MLC601 or MLC901, is a Chinese herbal combination used worldwide for stroke treatment. It contains herbal components and five hewan components. MLC601 contains herbal components and hewan components, while MLC901 has a similar herbal composition. NeuroAiD is used to support neurologic recovery after stroke and to aid cognitive function in Alzheimer’s disease. Studies show that NeuroAiD has potential in treating Alzheimer’s disease and is beneficial in both local and global stroke models and in the Kortikal culture. However, there is limited bibliometric res

APA, Harvard, Vancouver, ISO, and other styles

3

Salim Mahmood, Ahmed, Afaq M. Ammoo, Mayssam Hussein Mohammed Ali, et al. "Antiepileptic Effect of Neuroaid® on Strychnine-Induced Convulsions in Mice." Pharmaceuticals 15, no. 12 (2022): 1468. http://dx.doi.org/10.3390/ph15121468.

Full text

Abstract:

NeuroAid II, a folk Chinese Medicine, is currently used in Asia for the treatment of stroke. An experimental study demonstrated that NeuroAid enables neuronal cells to be more resistant to glutamate toxicity. This research was constructed to evaluate the efficacy of NeuroAid in the prevention of epilepsy (EP). Forty healthy adult male mice were used and divided into four groups (10 mice/group): normal control group; positive control group; NeuroAid-treated group (10 mg/kg); topiramate-treated group (10 mg/kg). The treatment continued for 7 days, and on the last day, EP was induced using strych

APA, Harvard, Vancouver, ISO, and other styles

4

Siow, Charles Hua Chiang. "Neuroaid in Stroke Recovery." European Neurology 60, no. 5 (2008): 264–66. http://dx.doi.org/10.1159/000155220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Dedy Chandra Hariyono, Hanis Setyono та Ida Bagus Budhi Surya Adnyana. "The Efficacy of NeuroAid™ (MLC601) in Modulating NF-κB Expression and Improving Outcomes in Traumatic Brain Injury: A Preclinical Study". Bioscientia Medicina : Journal of Biomedicine and Translational Research 9, № 6 (2025): 7728–40. https://doi.org/10.37275/bsm.v9i6.1309.

Full text

Abstract:

Background: Traumatic brain injury (TBI) represents a significant global health concern, leading to substantial mortality and long-term disability. The intricate pathophysiology of TBI involves primary mechanical damage followed by a cascade of secondary injury events, including neuroinflammation, apoptosis, and oxidative stress. The nuclear factor kappa B (NF-κB) signaling pathway plays a pivotal role in orchestrating the inflammatory response post-TBI and has emerged as a potential therapeutic target. This preclinical study aimed to investigate the efficacy of NeuroAid™ (MLC601), a tradition

APA, Harvard, Vancouver, ISO, and other styles

6

Kumar, Ramesh, Farizal Fadzil, Soon Bee, et al. "Neuroaid use in intracranial hemorrhage (ICH)." Journal of the Neurological Sciences 429 (October 2021): 118756. http://dx.doi.org/10.1016/j.jns.2021.118756.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Heurteaux, C., C. Widmann, H. Moha ou Maati, et al. "NeuroAiD: Properties for Neuroprotection and Neurorepair." Cerebrovascular Diseases 35, s1 (2013): 1–7. http://dx.doi.org/10.1159/000346228.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Tan, Chai-Hoon Nowel, David Choy, and Narayanaswamy Venketasubramanian. "NeuroAid II (MLC901) in Haemorrhagic Stroke." Case Reports in Neurology 12, Suppl. 1 (2020): 212–17. http://dx.doi.org/10.1159/000508588.

Full text

Abstract:

Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke. The use of NeuroAid II (MLC901), which comprises only the herbal components of MLC601, in haemorrhagic stroke has not been previously reported. Our patient is a 63-year-old male with a significant stroke risk factor of hypertension. He developed visual field defect, aphasia, unilateral weakness, and hemisensory loss. CT scan showed a left thalamic

APA, Harvard, Vancouver, ISO, and other styles

9

Kumar, Ramesh, Farizal Fadzil, Soon Bee, et al. "NeuroAiD use in traumatic brain injury (TBI)." Journal of the Neurological Sciences 429 (October 2021): 118220. http://dx.doi.org/10.1016/j.jns.2021.118220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Venketasubramanian, N., R. Kumar, L. Soertidewi, A. Abu Bakar, C. Laik, and R. Gan. "The NeuroAiD Safe Treatment (NeST) Registry: a protocol." BMJ Open 5, no. 11 (2015): e009866-e009866. http://dx.doi.org/10.1136/bmjopen-2015-009866.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lim, Y. A., L. A. Murray, M. K. P. Lai, and C. Chen. "NeuroAiD®(MLC601) and Amyloid Precursor Protein Processing." Cerebrovascular Diseases 35, s1 (2013): 30–37. http://dx.doi.org/10.1159/000346236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Navarro, Jose C., Mark C. Molina, Alejandro C. Baroque II, and Johnny K. Lokin. "The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients." Rehabilitation Research and Practice 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/506387.

Full text

Abstract:

Aim. We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke.Methods. This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (; 9 female) for three months and matching patients who did not receive MLC601 from our Stroke Data Bank. Outcome assessed was modified Rankin Scale (mRS) at three months and analyzed according to: (1) achieving a score of 0-2, (2) achieving a score of 0-1, and (3) mean change in scores from baseline.Results. At three months, 21 patients on MLC601 became independent as compared

APA, Harvard, Vancouver, ISO, and other styles

13

Venketasubramanian, Narayanaswamy, Chun Fan Lee, Sherry H. Young, et al. "Prognostic Factors and Pattern of Long-Term Recovery with MLC601 (NeuroAiD™) in the Chinese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study." Cerebrovascular Diseases 43, no. 1-2 (2016): 36–42. http://dx.doi.org/10.1159/000452285.

Full text

Abstract:

Background: The Chinese Medicine NeuroAiD Efficacy on Stroke recovery - Extension (CHIMES-E) study is among the few acute stroke trials with long-term outcome data. We aimed to evaluate the recovery pattern and the influence of prognostic factors on treatment effect of MLC601 over 2 years. Methods: The CHIMES-E study evaluated the 2 years outcome of subjects aged ≥18 years with acute ischemic stroke, National Institutes of Health Stroke Scale (NIHSS) score 6-14, pre-stroke modified Rankin Scale (mRS) score ≤1 included in a multicenter, randomized, double-blind, placebo-controlled trial of MLC6

APA, Harvard, Vancouver, ISO, and other styles

14

Quadrianti, Lilly, Diah Isnaini Asiati, and Maftuhah Nurrahmi. "Effect of Marketing Mix, Perception and Consumers’ Knowledge on NEUROAID Buying Decision at South Sumatera Region." International Journal of Marketing & Human Resource Research 5, no. 2 (2024): 95–111. http://dx.doi.org/10.47747/ijmhrr.v5i2.1775.

Full text

Abstract:

This research aims to determine the influence of the marketing mix (product, price, place, promotion) and consumer perception and knowledge on purchasing decisions for Neuroaid in the Southern Sumatra region. The type of research is descriptive research with a quantitative approach. This research uses independent variables, namely marketing mix (product, price, place, promotion) and perception and knowledge, and the dependent variable is purchasing decisions. The population is consumers of Neuroaid PT. Mersifarma, southern Sumatra, with a sample of 92 people taken using cluster sampling. The d

APA, Harvard, Vancouver, ISO, and other styles

15

Chen, Christopher L. H., Kamran Ikram, Qiu Anqi, Wong Tien Yin, Annabel Chen, and Narayanaswamy Venketasubramanian. "The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES)." Cerebrovascular Diseases 35, s1 (2013): 23–29. http://dx.doi.org/10.1159/000346234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Garcia, M. K. D., L. Penaserada, C. C. Diesta-Oropilla, R. Espiritu-Picar, and P. Noble. "The efficacy of neuroaid in stroke recovery: A meta-analysis." Journal of the Neurological Sciences 333 (October 2013): e578. http://dx.doi.org/10.1016/j.jns.2013.07.2021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Young, Sherry H. Y., Yudong Zhao, Angeline Koh, et al. "Safety Profile of MLC601 (Neuroaid®) in Acute Ischemic Stroke Patients: A Singaporean Substudy of the Chinese Medicine Neuroaid Efficacy on Stroke Recovery Study." Cerebrovascular Diseases 30, no. 1 (2010): 1–6. http://dx.doi.org/10.1159/000313398.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Huang, Suhua, Mingxia Lin, Xiaowei Pan, Qiwen Tan, and Kai-Leng Tan. "The potential of MLC901 (NeuroAiD II™), a traditional Chinese medicine." Neuroscience Research Notes 2, no. 2 (2019): 18–24. http://dx.doi.org/10.31117/neuroscirn.v2i2.32.

Full text

Abstract:

Stroke, also known as cerebral ischemia, is a common neurological disease. The therapeutic potential of MLC901 (NeuroAiD II™) has been reported in clinical trials on traumatic brain injury as well as in animal and cell models. MLC901 reduced the infarction size, ischemia-induced neurological deficits and pro-inflammatory infiltration of phagocyte. It also inhibited the ischemia-induced expression of pro-inflammatory mediators and Prx6, TLR4 signalling, and phosphorylation of NFκB. We found that the beneficial effects of MLC901 are in coherent with studies performed on the individual active ing

APA, Harvard, Vancouver, ISO, and other styles

19

Venketasubramanian, N., Sherry Young, San San Tay, et al. "Chinese Medicine NeuroAiD Efficacy Stroke Recovery - Extension Study (CHIMES-E Study): An Observational Multicenter Study to Investigate the Longer-Term Efficacy of NeuroAiD in Stroke Recovery." Cerebrovascular Diseases 35, s1 (2013): 18–22. http://dx.doi.org/10.1159/000346233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Venketasubramanian, Narayanaswamy, Rajesh B. Moorakonda, Qingshu Lu, and Christopher L. H. Chen. "Frequency and Clinical Impact of Serious Adverse Events on Post-Stroke Recovery with NeuroAiD (MLC601) versus Placebo: The CHInese Medicine Neuroaid Efficacy on Stroke Recovery Study." Cerebrovascular Diseases 49, no. 2 (2020): 192–99. http://dx.doi.org/10.1159/000506070.

Full text

Abstract:

Background: Most comparative clinical trials are designed to assess the treatment effect for efficacy endpoints, with less emphasis on the analysis of safety outcomes. However, an extensive analysis of safety data could demonstrate beneficial results in terms of effectiveness by reducing serious adverse events (SAEs), and their unfavourable clinical impact on the study population. We aimed to conduct an exploratory analysis of the CHInese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study safety database comparing the frequency of SAEs and their clinical impacts among subjects having

APA, Harvard, Vancouver, ISO, and other styles

21

Yanık, Tuğra, and Burcu Yanık. "Current neuroprotective agents in stroke." Turkish Journal of Physical Medicine and Rehabilitation 70, no. 2 (2024): 157–63. http://dx.doi.org/10.5606/tftrd.2024.15287.

Full text

Abstract:

What is expected from neuroprotection is to inhibit neuronal death and halt or decelerate the neuronal loss to lower the mortality rates, decrease disability, and improve the quality of life following an acute ischemic stroke. Several agents were described as neuroprotective up to date; however, there is still debate which to use in the neurorehabilitation of stroke patients, in terms of both efficacy and also safety. In this review, we discuss the agents, citicoline, cerebrolysin and MLC901 (NeuroAiD II), the three agents which have started to be used frequently in neurorehabilitation clinics

APA, Harvard, Vancouver, ISO, and other styles

22

Chen, Christopher L. H., Qingshu Lu, Rajesh Babu Moorakonda, et al. "Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial." Journal of the American Medical Directors Association 23, no. 3 (2022): 379–86. http://dx.doi.org/10.1016/j.jamda.2021.10.018.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lee Lee, Wei Thye, Christopher Chen, and Yun-An Lim. "P2-032: Effects of Neuroaid II (MLC901) on App Processing and TAU Phosphorylation." Alzheimer's & Dementia 12 (July 2016): P620—P621. http://dx.doi.org/10.1016/j.jalz.2016.06.1236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Venketasubramanian, Narayanaswamy, Yogesh Pokharkar, Jia Hui Chai, and Christopher Li Hsian Chen. "Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD." Journal of Cardiovascular Development and Disease 10, no. 3 (2023): 117. http://dx.doi.org/10.3390/jcdd10030117.

Full text

Abstract:

Despite recent progress with revascularisation interventions after acute ischemic stroke, many patients remain disabled after stroke. Using data from a multi-centre, randomised, double-blind, placebo-controlled trial of a neuro-repair treatment (NeuroAiD/MLC601) with a long-term follow-up, we analysed the savings in time to functional recovery, measured by a modified Rankin Scale (mRS) score of 0 or 1, in patients receiving a 3-month oral course of MLC601. Analysis of time to recovery was assessed by a log-rank test and hazard ratios (HRs) adjusted for prognosis factors. A total of 548 patient

APA, Harvard, Vancouver, ISO, and other styles

25

Han, Haijun, Zhongli Yang, Sulie L. Chang, and Ming D. Li. "Modulatory Effects of Nicotine on neuroHIV/neuroAIDS." Journal of Neuroimmune Pharmacology 13, no. 4 (2018): 467–78. http://dx.doi.org/10.1007/s11481-018-9806-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Chen, C. L. H., S. H. Y. Young, H. H. Gan, et al. "Chinese Medicine Neuroaid Efficacy on Stroke Recovery: A Double-Blind, Placebo-Controlled, Randomized Study." Stroke 44, no. 8 (2013): 2093–100. http://dx.doi.org/10.1161/strokeaha.113.002055.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Venketasubramanian, Narayanaswamy, Sherry H. Young, San San Tay, et al. "CHInese Medicine NeuroAiD Efficacy on Stroke Recovery - Extension Study (CHIMES-E): A Multicenter Study of Long-Term Efficacy." Cerebrovascular Diseases 39, no. 5-6 (2015): 309–18. http://dx.doi.org/10.1159/000382082.

Full text

Abstract:

Background: The CHInese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) study was an international randomized double-blind placebo-controlled trial of MLC601 (NeuroAiD) in subjects with cerebral infarction of intermediate severity within 72 h. CHIMES-E (Extension) aimed at evaluating the effects of the initial 3-month treatment with MLC601 on long-term outcome for up to 2 years. Methods: All subjects randomized in CHIMES were eligible for CHIMES-E. Inclusion criteria for CHIMES were age ≥18, baseline National Institute of Health Stroke Scale of 6-14, and pre-stroke modified Rankin Scale

APA, Harvard, Vancouver, ISO, and other styles

28

Nasehi, Mohammad, Setareh Nouri Zadeh-Tehrani, Fatemeh Khakpai, and Mohammad-Reza Zarrindast. "A possible neuroprotective property of ethanol and/or NeuroAiD on the modulation of cognitive function." Neurotoxicology and Teratology 82 (November 2020): 106927. http://dx.doi.org/10.1016/j.ntt.2020.106927.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Kumar, Ramesh, Ohnmar Htwe, Azmi Baharudin, et al. "Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury." JMIR Research Protocols 5, no. 4 (2016): e230. http://dx.doi.org/10.2196/resprot.6275.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Theadom, A., S. Barker‐Collo, K. M. Jones, P. Parmar, R. Bhattacharjee, and V. L. Feigin. "MLC 901 (NeuroAiD II ™) for cognition after traumatic brain injury: a pilot randomized clinical trial." European Journal of Neurology 25, no. 8 (2018): 1055. http://dx.doi.org/10.1111/ene.13653.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Fabiaña, Natasha L., Christopher L. H. Chen, Narayanaswamy Venketasubramanian, Chun Fan Lee, K. S. Lawrence Wong, and Deidre Anne De Silva. "Sex and the treatment effect in the Chinese Medicine NeuroAiD Efficacy on Stroke recovery (CHIMES) trial." Journal of Clinical Neuroscience 33 (November 2016): 269–70. http://dx.doi.org/10.1016/j.jocn.2016.04.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Heurteaux, C., C. Gandin, M. Borsotto, et al. "Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo." Neuropharmacology 58, no. 7 (2010): 987–1001. http://dx.doi.org/10.1016/j.neuropharm.2010.01.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Harandi, A. A., R. Abolfazli, A. Hatemian, et al. "Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial." Stroke Research and Treatment 2011 (2011): 1–5. http://dx.doi.org/10.4061/2011/721613.

Full text

Abstract:

Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke.Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months.Results. Sex, age, elapsed time from stroke onset, and risk factors in the treatment group were not significantly different from placebo group at baseline

APA, Harvard, Vancouver, ISO, and other styles

34

Ohnmar, Htwe, Ramesh Kumar, Azmi Baharudin, et al. "Safety and efficacy of MLC601/MLC901 (NeuroAiD) amongst patients who sustain severe spinal cord injury (SATURN study)." Journal of the Neurological Sciences 429 (October 2021): 118574. http://dx.doi.org/10.1016/j.jns.2021.118574.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Siddiqui, Fahad Javaid, Narayanaswamy Venketasubramanian, Edwin Shih-Yen Chan, and Christopher Chen. "Efficacy and Safety of MLC601 (NeuroAiD®), a Traditional Chinese Medicine, in Poststroke Recovery: A Systematic Review." Cerebrovascular Diseases 35, s1 (2013): 8–17. http://dx.doi.org/10.1159/000346231.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Chan, H. Y. A., and L. W. Stanton. "A pharmacogenomic profile of human neural progenitors undergoing differentiation in the presence of the traditional Chinese medicine NeuroAiD." Pharmacogenomics Journal 16, no. 5 (2016): 461–71. http://dx.doi.org/10.1038/tpj.2016.21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Bavarsad shahripour, Reza, Ahmad Hemati, and Ana Hosseinzadeh maleki. "A Randomized trial to assess the long-term safety of NeuroAiD among Caucasian patients with acute ischemic stroke." Chinese Journal of Integrative Medicine 20, no. 11 (2014): 812–17. http://dx.doi.org/10.1007/s11655-014-1687-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Torabinejad, Sepehr, Mehrdad Hashemi, and Mohammad Nasehi. "The Expression Changes of the Mcl-1 Gene Following Cholestasis and Treatment by Neuroaid in Striatum of Male Rats." Medical Journal of Tabriz University of Medical Sciences and Health Services 41, no. 2 (2019): 22–29. http://dx.doi.org/10.34172/mj.2019.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Venketasubramanian, N., C. L. H. Chen, R. N. Gan, et al. "A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate Chinese Medicine Neuroaid Efficacy on Stroke Recovery (CHIMES Study)." International Journal of Stroke 4, no. 1 (2009): 54–60. http://dx.doi.org/10.1111/j.1747-4949.2009.00237.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Venketasubramanian, Narayanaswamy, Tseng Tsai Yeo, and Christopher Li Hsian Chen. "Translational Medicine in Acute Ischemic Stroke and Traumatic Brain Injury—NeuroAiD Trials, from Traditional Beliefs to Evidence-Based Therapy." Biomolecules 14, no. 6 (2024): 680. http://dx.doi.org/10.3390/biom14060680.

Full text

Abstract:

Acute ischemic stroke (AIS) and traumatic brain injury (TBI) are two severe neurological events, both being major causes of death and prolonged impairment. Their incidence continues to rise due to the global increase in the number of people at risk, representing a significant burden on those remaining impaired, their families, and society. These molecular and cellular mechanisms of both stroke and TBI present similarities that can be targeted by treatments with a multimodal mode of action, such as traditional Chinese medicine. Therefore, we performed a detailed review of the preclinical and cl

APA, Harvard, Vancouver, ISO, and other styles

41

Ranuh, I. G. M. Aswin R., Gadis Meinar Sari, Budi Utomo, Nur Setiawan Suroto, and Asra Al Fauzi. "Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD IITM) for Acute Ischemic Brain Injury in Animal Models." Journal of Evidence-Based Integrative Medicine 26 (January 1, 2021): 2515690X2110392. http://dx.doi.org/10.1177/2515690x211039219.

Full text

Abstract:

Introduction. Moleac (MLC) 901 is a traditional Chinese medication approved by the Sino Food and Drug Administration in 2001 for treating stroke. This study aims to analyze the efficacy of MLC901 in animal stroke models after medial cerebral artery occlusion (MCAO). Methods. Literature selection was performed according to the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA) 2015. Inclusion criteria for the experimental studies were the use of animal models, publication in English between 1990 and 2020, information regarding the intervention

APA, Harvard, Vancouver, ISO, and other styles

42

Quintard, H., M. Borsotto, J. Veyssiere, C. Gandin, M. Lazdunski, and C. Heurteaux. "Effets neuroprotecteurs et neuroprolifératifs du MLC 601 et 901 (neuroaid) sur deux modèles ischémiques chez la souris et le rat." Annales Françaises d'Anesthésie et de Réanimation 32 (September 2013): A127—A128. http://dx.doi.org/10.1016/j.annfar.2013.07.247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Kho, G. S. "CLINICAL EXPERIENCE OF THERAPEUTIC BENEFIT OF NEUROAID^TM (MLC901) IN PEDIATRICS: REVIEW OF THREE CASES OF SEVERE TRAUMATIC BRAIN INJURY." National Journal of Neurology 1, no. 24 (2024): 68–75. https://doi.org/10.61788/njn.v1i24.11.

Full text

Abstract:

Background. Traumatic Brain Injury (TBI) results in acute and chronic sequalae involving structural and functional impairments especially in children. This leads to significant disability, which affects child’s development and adaptive functions. Elderly patients and children have a high risk of developing long-term disability, which have no proven treatments. MLC901 (NeuroAiDTM II) is a combination of natural herbal formulations with origins from Traditional Chinese Medicine which has shown to be safe and aids in neurological recovery after brain injuries. Objective. There is an existing know

APA, Harvard, Vancouver, ISO, and other styles

44

SALEH, ARMAN YURISALDI, Dwi Arwandi Yogi Saputra, Riezky Valentina, and Tirta Darmawan Susanto. "Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024." F1000Research 14 (May 15, 2025): 275. https://doi.org/10.12688/f1000research.160416.2.

Full text

Abstract:

1) Introduction Cognitive enhancers, also known as nootropics, aim to improve cognitive functions, such as memory and attention. Despite their potential benefits, the challenges include scientific validation, ethical considerations, and regulatory hurdles. This bibliometric study analyzes literature from Scopus to identify key trends, influential authors, and research gaps, providing guidance for future research. 2) Methods This study employs a literature review methodology to gather data from the Scopus database on Neuroaid, analyzing it using Biblioshiny and VOSviewer software. The focus was

APA, Harvard, Vancouver, ISO, and other styles

45

SALEH, ARMAN YURISALDI, Dwi Arwandi Yogi Saputra, Riezky Valentina, and Tirta Darmawan Susanto. "Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024." F1000Research 14 (March 7, 2025): 275. https://doi.org/10.12688/f1000research.160416.1.

Full text

Abstract:

1) Introduction Cognitive enhancers, also known as nootropics, aim to improve cognitive functions, such as memory and attention. Despite their potential benefits, the challenges include scientific validation, ethical considerations, and regulatory hurdles. This bibliometric study analyzes literature from Scopus to identify key trends, influential authors, and research gaps, providing guidance for future research. 2) Methods This study employs a literature review methodology to gather data from the Scopus database on Neuroaid, analyzing it using Biblioshiny and VOSviewer software. The focus was

APA, Harvard, Vancouver, ISO, and other styles

46

Venketasubramanian, Narayanaswamy, Chun Fan Lee, K. S. Lawrence Wong, and Christopher L. H. Chen. "The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)." Journal of Evidence-Based Medicine 8, no. 3 (2015): 149–53. http://dx.doi.org/10.1111/jebm.12170.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Bavarsad Shahripour, Reza, Gholamreza Shamsaei, Hosein Pakdaman, et al. "The effect of NeuroAiD™ (MLC601) on cerebral blood flow velocity in subjects' post brain infarct in the middle cerebral artery territory." European Journal of Internal Medicine 22, no. 5 (2011): 509–13. http://dx.doi.org/10.1016/j.ejim.2011.01.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Navarro, Jose C., Christopher Li Hsian Chen, Pedro Danilo J. Lagamayo, et al. "CHIMES-I: Sub-Group Analyzes of the Effects of NeuroAiD According to Baseline Brain Imaging Characteristics among Patients Randomized in the CHIMES Study." International Journal of Stroke 8, no. 6 (2013): 491–94. http://dx.doi.org/10.1111/ijs.12044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Arsovska, Anita Ante, and Narayanaswamy Venketasubramanian. "Use of MLC901 in cerebral venous sinus thrombosis: Three case reports." World Journal of Clinical Cases 12, no. 2 (2024): 346–53. http://dx.doi.org/10.12998/wjcc.v12.i2.346.

Full text

Abstract:

BACKGROUND Cerebral venous sinus thrombosis (CVT) is rare cause of cerebrovascular disease. The incidence is 0.5% of all stroke. The majority of affected patients are young adults (mean age: 35-40 years) with mild to moderate disabilities. Poor outcome with severe disability is seen in 13% of cases. Early diagnosis and treatment are important for good outcomes and preventing complications. Treatment options are limited and mostly based on consensus. NeuroAiD II™ (MLC901; Moleac Pte, Ltd, Singapore) has a potential beneficial role in post-stroke recovery, by aiding the natural brain recovery pr

APA, Harvard, Vancouver, ISO, and other styles

50

Anisovska, Anita, Mariusz Janta, Anna Tomašová, Slavomír Guťan, Barbora Garajová, and Iveta Nikolová. "Real-world effectiveness of MLC901 in subjects after brain injuries in the eastern European population: A preliminary result of neuroaid safe treatment (nest) registry." Journal of the Neurological Sciences 429 (October 2021): 119652. http://dx.doi.org/10.1016/j.jns.2021.119652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!